Comparison · NCT00801229-2e2c2b04
Vyvanse vs Placebo: Participants Experiencing Collisions During Surprise Events in Driving Simulator
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vyvanse vs Placebo: Participants Experiencing Collisions During Surprise Events in Driving Simulator. Trial comparisons, record NCT00801229-2e2c2b04. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00801229-2e2c2b04
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.258 | 0.137 | 0.432 | wilson | |
| Risk in group 2 | 0.567 | 0.392 | 0.726 | wilson | |
| Risk difference, group 1 minus group 2 | -0.309 | -0.509 | -0.0618 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.455 | 0.232 | 0.893 | log | |
| Odds ratio, group 1 over group 2 | 0.266 | 0.0902 | 0.784 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vyvanse than on Placebo | 3.24 | 1.97 | 16.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vyvanse | 8 | 31 | OG000 | |
| Group 2 | Placebo | 17 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Participants Experiencing Collisions During Surprise Events in Driving Simulator
- Description
Initial results from a one hour driving simulation in the MIT AgeLab Driving Simulator as compared to second session in the simulator following a 6-week trial on Lisdexamfetamine or placebo. During the simulation, surprise events, designed to test the participant's attention and driving, occurred. This outcome presents the difference in number of collisions experience by individuals treated with Vyvanse or Placebo.
- Time frame
- 6 weeks
- Population
- Participants who completed the protocol, including endpoint Driving Simulation assessment, were analyzed (61 in total).
Source ClinicalTrials.gov
Trial
- Title
- Effect of Vyvanse on Driving in Young Adults With ADHD
- NCT number
- NCT00801229
- Phases
- PHASE4
- Conditions
- Attention Deficit/Hyperactivity Disorder(ADHD)
- Interventions
- Vyvanse, Placebo
- Lead sponsor
- Massachusetts General Hospital
- Results first posted
- 2011-08-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00801229?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00801229-2e2c2b04